Devonian Health Group Inc. (DVHGF)
Devonian Health Group Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Québec, QC, CA. The stock last traded at $7.00, up 0.00% on the session, giving a market capitalisation of $19.5M. On trailing twelve-month figures it carries a trailing P/E of -4.45, a net margin of -227.7%. Its beta of 1.26 implies it has historically moved more than the broad market.
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Devonian Health Group Inc. is most often compared with the following Healthcare names: